{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for telotristat root_names_stdName in Standardized Name (approximate match)
Class (Stereo):
CHEMICAL (ACHIRAL)
Ocaperidone [R 79598] is an equipotent antagonist of central dopamine D2 and serotonin2 receptors being investigated as a potential antipsychotic agent. Ocaperidone is a benzisoxazol piperidine antipsychotic primarily binds and with high affinity to 5-HT2 (serotonin) receptors, alpha1 and alpha 2 adrenergic receptors, dopamine D2 receptors and histamine H1 receptors. Ocaperidone is an antagonist primarily at the 5HT and D2 receptors. A proposed mechanism of action is the central D2 receptor blockade which is common to all neuroleptics that are used to treat positive symptoms of schizophrenia.
Class (Stereo):
CHEMICAL (RACEMIC)
Tienoxolol is a benzoic acid derivative patented by Centre d'Activite et de Recherche Pharmaceutique Industrielle Biologique et Medicale as β-sympatholytic and diuretic. Tienoxolol acts as a beta-adrenergic receptor antagonist shows potent diuretic and natriuretic activity and, besides that anti-hypertension activity in preclinical models. In clinical trials, Tienoxolol significantly and dose-dependently reduced exercise-induced tachycardia. This effect started 1 h after drug administration, peaked between 4 h and 6 h and lasted at least 12 h.
Status:
Investigational
Source:
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1978;30(4):299-304.: Not Applicable Human clinical trial Completed Gastrointestinal Diseases
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Metiamide is an antagonist of histamine H2-receptors synthesized at Smith Kline & French Laboratories. It potently inhibited gastric acid secretion. Metiamide demonstrated promising clinical effects in patients with duodenal ulcers but questionable safety.
Class (Stereo):
CHEMICAL (ACHIRAL)
FLOSATIDIL is an antihypertensive drug discontinued in Phase II for angina pectoris.
Status:
Investigational
Source:
INN:fluzoperine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Fluzoperine was studied as an antiarrhythmic agent. However, information about the current use of this drug is not available.
Status:
Investigational
Source:
INN:fopirtoline [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Fomidacillin (also known as BRL 36650) is a type of penicillin with antibacterial activity. Studies on volunteers have shown that the drug possessed the bactericidal activity and could be a candidate for the treatment of gram-negative bacillary infections. However, information about the further development of this drug is not available.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Tinofedrine is a dithienylamine derivative patented by Deutsche Gold- und Silber-Scheideanstalt vorm. Roessler for improvement of cerebral and peripheral blood flow. In anesthetized dogs, Tinofedrine causes a remarkable increase of cardiac output by positive inotropic and chronotropic stimulation of the heart and simultaneous reduction of peripheral vascular resistance. In comparison with typical beta-agonists Tinofedrine at isotropically equieffective doses, has a much weaker effect on the heart rate. In coronary circulation, Tinofedrine causes vasodilation so that in a therapeutic dose range increased workload is equalized by sufficient myocardial supply.
Status:
Investigational
Source:
INN:metescufylline [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ACHIRAL)
Lintopride is a benzamide, eliciting prokinetic properties on the upper gut in several animal models. Lintopride increases gastric emptying, stimulates antral and duodenal motility and accelerates intestinal transit in animals. In canines it also increases lower oesophageal sphincter (LOS) pressure and reinforces peristaltic waves after wet swallowing, indicating a stimulatory action which could potentially be greater than that of metoclopramide. The 5HT-4 agonist lintopride increases LOS basal pressure and the amplitude of peristaltic waves of the oesophagus following a single intravenous dose in healthy subjects. The action of lintopride on LOS basal pressure and oesophageal peristaltic waves could be beneficial in patients with gastro-oesophageal reflux disease.